Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04159831 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions
A Phase 2 study, sponsored by Rein Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT04159831 is a Phase 2 study that has completed, run by Rein Therapeutics. The registered enrollment target is 44 participants.
The verdict
NCT04159831, a Phase 2 study, has completed, sponsored by Rein Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
The LTI-01-2001 study is a double-blind, placebo-controlled, Phase 2 study to evaluate LTI-01 (single-chain urokinase plasminogen activator, scuPA) in patients with infected, non-draining pleural effusions.
Interventions
- DRUG Placebo
- DRUG LTI-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2020-09-26 |
| Est. Completion | 2022-07-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04159831
The ClinicalTrials.gov registry entry for NCT04159831 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rein Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04159831 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04159831 about?
NCT04159831 is a clinical study titled "A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions". The LTI-01-2001 study is a double-blind, placebo-controlled, Phase 2 study to evaluate LTI-01 (single-chain urokinase plasminogen activator, scuPA) in patients with infected, non-draining pleural effusions.
What is the current status of trial NCT04159831?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2020-09-26. Estimated completion is 2022-07-28.
What interventions are being tested in trial NCT04159831?
The interventions under investigation include: Placebo (DRUG), LTI-01 (DRUG).
Who is sponsoring clinical trial NCT04159831?
This trial is sponsored by Rein Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.